Cargando…

ALS-specific cognitive and behavior changes associated with advancing disease stage in ALS

OBJECTIVE: To elucidate the relationship between disease stage in amyotrophic lateral sclerosis (ALS), as measured with the King's Clinical Staging System, and cognitive and behavioral change, measured with the Edinburgh Cognitive and Behavioural ALS Screen (ECAS). METHODS: A large multicenter...

Descripción completa

Detalles Bibliográficos
Autores principales: Crockford, Christopher, Newton, Judith, Lonergan, Katie, Chiwera, Theresa, Booth, Tom, Chandran, Siddharthan, Colville, Shuna, Heverin, Mark, Mays, Iain, Pal, Suvankar, Pender, Niall, Pinto-Grau, Marta, Radakovic, Ratko, Shaw, Christopher E., Stephenson, Laura, Swingler, Robert, Vajda, Alice, Al-Chalabi, Ammar, Hardiman, Orla, Abrahams, Sharon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6177274/
https://www.ncbi.nlm.nih.gov/pubmed/30209236
http://dx.doi.org/10.1212/WNL.0000000000006317
_version_ 1783361840344989696
author Crockford, Christopher
Newton, Judith
Lonergan, Katie
Chiwera, Theresa
Booth, Tom
Chandran, Siddharthan
Colville, Shuna
Heverin, Mark
Mays, Iain
Pal, Suvankar
Pender, Niall
Pinto-Grau, Marta
Radakovic, Ratko
Shaw, Christopher E.
Stephenson, Laura
Swingler, Robert
Vajda, Alice
Al-Chalabi, Ammar
Hardiman, Orla
Abrahams, Sharon
author_facet Crockford, Christopher
Newton, Judith
Lonergan, Katie
Chiwera, Theresa
Booth, Tom
Chandran, Siddharthan
Colville, Shuna
Heverin, Mark
Mays, Iain
Pal, Suvankar
Pender, Niall
Pinto-Grau, Marta
Radakovic, Ratko
Shaw, Christopher E.
Stephenson, Laura
Swingler, Robert
Vajda, Alice
Al-Chalabi, Ammar
Hardiman, Orla
Abrahams, Sharon
author_sort Crockford, Christopher
collection PubMed
description OBJECTIVE: To elucidate the relationship between disease stage in amyotrophic lateral sclerosis (ALS), as measured with the King's Clinical Staging System, and cognitive and behavioral change, measured with the Edinburgh Cognitive and Behavioural ALS Screen (ECAS). METHODS: A large multicenter observational cohort of 161 cross-sectional patients with ALS and 80 healthy matched controls were recruited across 3 research sites (Dublin, Edinburgh, and London). Participants were administered the ECAS and categorized into independent groups based on their King's clinical disease stage at time of testing. RESULTS: Significant differences were observed between patients and controls on all subtests of the ECAS except for visuospatial functioning. A significant cross-sectional effect was observed across disease stages for ALS-specific functions (executive, language, letter fluency) and ECAS total score but not for ALS-nonspecific functions (memory, visuospatial). Rates of ALS-specific impairment and behavioral change were also related to disease stage. The relationship between cognitive function and disease stage may be due to letter fluency impairment, whereas higher rates of all behavioral domains were seen in later King's stage. The presence of bulbar signs, but not site of onset, was significantly related to ALS-specific, ECAS total, and behavioral scores. CONCLUSION: ALS-specific cognitive deficits and behavioral impairment are more frequent with more severe disease stage. By end-stage disease, only a small percentage of patients are free of neuropsychological impairment. The presence of bulbar symptoms exaggerates the differences observed between disease stages. These findings suggest that cognitive and behavioral change should be incorporated into ALS diagnostic criteria and should be included in future staging systems.
format Online
Article
Text
id pubmed-6177274
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-61772742018-10-11 ALS-specific cognitive and behavior changes associated with advancing disease stage in ALS Crockford, Christopher Newton, Judith Lonergan, Katie Chiwera, Theresa Booth, Tom Chandran, Siddharthan Colville, Shuna Heverin, Mark Mays, Iain Pal, Suvankar Pender, Niall Pinto-Grau, Marta Radakovic, Ratko Shaw, Christopher E. Stephenson, Laura Swingler, Robert Vajda, Alice Al-Chalabi, Ammar Hardiman, Orla Abrahams, Sharon Neurology Article OBJECTIVE: To elucidate the relationship between disease stage in amyotrophic lateral sclerosis (ALS), as measured with the King's Clinical Staging System, and cognitive and behavioral change, measured with the Edinburgh Cognitive and Behavioural ALS Screen (ECAS). METHODS: A large multicenter observational cohort of 161 cross-sectional patients with ALS and 80 healthy matched controls were recruited across 3 research sites (Dublin, Edinburgh, and London). Participants were administered the ECAS and categorized into independent groups based on their King's clinical disease stage at time of testing. RESULTS: Significant differences were observed between patients and controls on all subtests of the ECAS except for visuospatial functioning. A significant cross-sectional effect was observed across disease stages for ALS-specific functions (executive, language, letter fluency) and ECAS total score but not for ALS-nonspecific functions (memory, visuospatial). Rates of ALS-specific impairment and behavioral change were also related to disease stage. The relationship between cognitive function and disease stage may be due to letter fluency impairment, whereas higher rates of all behavioral domains were seen in later King's stage. The presence of bulbar signs, but not site of onset, was significantly related to ALS-specific, ECAS total, and behavioral scores. CONCLUSION: ALS-specific cognitive deficits and behavioral impairment are more frequent with more severe disease stage. By end-stage disease, only a small percentage of patients are free of neuropsychological impairment. The presence of bulbar symptoms exaggerates the differences observed between disease stages. These findings suggest that cognitive and behavioral change should be incorporated into ALS diagnostic criteria and should be included in future staging systems. Lippincott Williams & Wilkins 2018-10-09 /pmc/articles/PMC6177274/ /pubmed/30209236 http://dx.doi.org/10.1212/WNL.0000000000006317 Text en Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License 4.0 (CC BY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Article
Crockford, Christopher
Newton, Judith
Lonergan, Katie
Chiwera, Theresa
Booth, Tom
Chandran, Siddharthan
Colville, Shuna
Heverin, Mark
Mays, Iain
Pal, Suvankar
Pender, Niall
Pinto-Grau, Marta
Radakovic, Ratko
Shaw, Christopher E.
Stephenson, Laura
Swingler, Robert
Vajda, Alice
Al-Chalabi, Ammar
Hardiman, Orla
Abrahams, Sharon
ALS-specific cognitive and behavior changes associated with advancing disease stage in ALS
title ALS-specific cognitive and behavior changes associated with advancing disease stage in ALS
title_full ALS-specific cognitive and behavior changes associated with advancing disease stage in ALS
title_fullStr ALS-specific cognitive and behavior changes associated with advancing disease stage in ALS
title_full_unstemmed ALS-specific cognitive and behavior changes associated with advancing disease stage in ALS
title_short ALS-specific cognitive and behavior changes associated with advancing disease stage in ALS
title_sort als-specific cognitive and behavior changes associated with advancing disease stage in als
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6177274/
https://www.ncbi.nlm.nih.gov/pubmed/30209236
http://dx.doi.org/10.1212/WNL.0000000000006317
work_keys_str_mv AT crockfordchristopher alsspecificcognitiveandbehaviorchangesassociatedwithadvancingdiseasestageinals
AT newtonjudith alsspecificcognitiveandbehaviorchangesassociatedwithadvancingdiseasestageinals
AT lonergankatie alsspecificcognitiveandbehaviorchangesassociatedwithadvancingdiseasestageinals
AT chiweratheresa alsspecificcognitiveandbehaviorchangesassociatedwithadvancingdiseasestageinals
AT boothtom alsspecificcognitiveandbehaviorchangesassociatedwithadvancingdiseasestageinals
AT chandransiddharthan alsspecificcognitiveandbehaviorchangesassociatedwithadvancingdiseasestageinals
AT colvilleshuna alsspecificcognitiveandbehaviorchangesassociatedwithadvancingdiseasestageinals
AT heverinmark alsspecificcognitiveandbehaviorchangesassociatedwithadvancingdiseasestageinals
AT maysiain alsspecificcognitiveandbehaviorchangesassociatedwithadvancingdiseasestageinals
AT palsuvankar alsspecificcognitiveandbehaviorchangesassociatedwithadvancingdiseasestageinals
AT penderniall alsspecificcognitiveandbehaviorchangesassociatedwithadvancingdiseasestageinals
AT pintograumarta alsspecificcognitiveandbehaviorchangesassociatedwithadvancingdiseasestageinals
AT radakovicratko alsspecificcognitiveandbehaviorchangesassociatedwithadvancingdiseasestageinals
AT shawchristophere alsspecificcognitiveandbehaviorchangesassociatedwithadvancingdiseasestageinals
AT stephensonlaura alsspecificcognitiveandbehaviorchangesassociatedwithadvancingdiseasestageinals
AT swinglerrobert alsspecificcognitiveandbehaviorchangesassociatedwithadvancingdiseasestageinals
AT vajdaalice alsspecificcognitiveandbehaviorchangesassociatedwithadvancingdiseasestageinals
AT alchalabiammar alsspecificcognitiveandbehaviorchangesassociatedwithadvancingdiseasestageinals
AT hardimanorla alsspecificcognitiveandbehaviorchangesassociatedwithadvancingdiseasestageinals
AT abrahamssharon alsspecificcognitiveandbehaviorchangesassociatedwithadvancingdiseasestageinals